&w=3840&q=100)
Why did Shilpa Medicare share jump 5% in trade today? top details here
Around 1:30 PM, Shilpa Medicare share price was trading 4.93 per cent higher at ₹938.50. By comparison, BSE Sensex was trading 0.08 per cent lower at 82,640.01 levels. CATCH STOCK MARKET LIVE UPDATES TODAY
Why did Shilpa Medicare share price rise in trade today?
Shilpa Medicare share price gained in trade after the company announced a positive regulatory update from the US health regulator, United States Food and Drug Administration (USFDA).
The pharma firm said its Unit VI at Dabaspet, Bengaluru received an Establishment Inspection Report (EIR) with a 'Voluntary Action Indicated' (VAI) classification from the USFDA. The EIR followed a Good Manufacturing Practices (GMP) inspection conducted between October 24-30, 2024.
In an exchange filing, Shilpa Medicare said, 'This is to inform you that Shilpa Medicare Limited, Unit VI, Dabaspet, Bengaluru, Karnataka, India has received EIR with VAI (Voluntary Action Indicated) classification, from USFDA, for the GMP inspection which was conducted from October 24 – 30, 2024.'
The unit is capable of manufacturing, packaging, testing, storage and distribution of two types of complex dosage forms including Oral Dissolving Films and Transdermal Systems.
Meanwhile, the unit already holds approvals from key global regulators, including EMA (Europe), MHRA (UK), SFDA (Saudi Arabia), and TGA (Australia). It currently supplies oral film products to the US and other markets, while filings for transdermal products have been made in Europe.
Shilpa Medicare Q4 results
Shilpa Medicare reported a mixed set of numbers in Q4FY25. While revenue from operations grew 13.3 per cent year-on-year (Y-o-Y) to ₹330.80 crore and earnings before interest, tax, depreciation and amortisation (Ebitda) rose 15 per cent to ₹84 crore, net profit (PAT) declined 40.8 per cent to ₹14.51 crore.
About Shilpa Medicare
Shilpa Medicare Limited is a global pharmaceutical company with a strong presence in regulated markets such as the USA, Europe, and Japan.
The company specialises in the development and manufacturing of Active Pharmaceutical Ingredients (APIs) and finished dosage formulations, with a particular focus on oncology.
Its product range includes tablets, capsules, injectables, and transdermal patches, all manufactured to meet international quality standards. Additionally, Shilpa Medicare provides end-to-end Contract Development and Manufacturing Organisation (CDMO) services, catering to a wide spectrum of pharmaceutical needs.
Beyond its core offerings, the company is actively investing in research and development, focusing on novel drug delivery systems and expanding into emerging therapy areas, including biotech products.
The market capitalisation of Shilpa Medicare is ₹9,177.68 crore, according to BSE. The company falls under the BSE SmallCap category.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
&w=3840&q=100)
Business Standard
an hour ago
- Business Standard
Microcap stock hits multi-year high, up 20% in weak market on huge volumes
Kinetic Engineering share price today Shares of Kinetic Engineering hit a multi-year high of ₹351.75, zooming 20 per cent on the BSE in Thursday's intraday trade, in an otherwise weak market. The stock price of the microcap auto ancillary company was trading close to its all-time high level of ₹380, which it touched on June 17, 1996. At 02:08 PM, Kinetic Engineering shares were quoting 17 per cent higher at ₹342.35 as compared to a 0.22 per cent decline in the BSE Sensex. Average trading volumes on the counter jumped over 10-fold, with 409,000 shares changing hands on the BSE till the time of writing this report, data shows. In the past one week, the stock price of Kinetic Engineering has surged 35 per cent. Further, it has zoomed 146 per cent from its 52-week low of ₹143, touched on January 13, 2025. Currently, Kinetic Engineering is trading 'X' group on the BSE. Equity shares classified under 'X' group are only listed/traded on the BSE. The company's market capitalisation stands at ₹801 crore. What's driving the Kinetic Engineering stock price higher? In May 2025, Kinetic Engineering announced that it has, officially, granted a brand license to its subsidiary company, Kinetic Watts and Volts Ltd. (KWV), to enter the electric vehicle (EV) segment. Kinetic Watts and Volts Ltd., incorporated on September 27, 2022, was established with the mandate to explore alternative opportunities in the electric vehicle space. Under the agreement, KWV will have the non-exclusive right to use the Kinetic brand name and trademarks for its EV business, for an initial period of three years. At the end of the initial three-year licensing period, Kinetic Engineering and KWV will review and renew the licensing terms to align with the group's long-term vision, market dynamics, and any potential expansion into new categories or international markets. Kinetic Engineering is a key supplier of EV components including gearboxes, axles, and chassis, playing a crucial role in India's evolving EV supply chain. Additionally, Kinetic Group recently ventured into the battery manufacturing sector under a separate group company operating under the brand 'Range X', further expanding its footprint across the electric mobility ecosystem. Kinetic Engineering is the flagship company of the Kinetic Group, with over five decades of manufacturing excellence. Headquartered in Pune and led by Ajinkya Firodia, Vice Chairman & Managing Director, Kinetic Engineering has been a pioneer in India's automotive industry. The company is engaged in the manufacturing and supply of automotive components. The company caters to both domestic and international markets. The company's clientele includes Renault, American Axle, Tata Motors, Mahindra & Mahindra, Ashok Leyland, Magna Powertrain, Sonalika Tractors, Carraro Products, among others.
&w=3840&q=100)
Business Standard
an hour ago
- Business Standard
Breakout stocks: ixigo, 5 other smallcap shares ripe for up to 32% rally
Smallcap stocks - ixigo, Hinduja Global, Gujarat Apollo, Radhika Jeweltech, Ksolves India and Mirc Electronics witnessed a breakout on the daily chart on Thursday, July 17. Rex Cano Mumbai Listen to This Article Smallcap shares were seen outperforming the broader market on Thursday. As of 1 PM, the BSE SmallCap index was up 0.4 per cent, while the BSE Sensex was down 0.2 per cent, and the MidCap index up 0.2 per cent. Out of the 250 BSE Smallcap index shares, 156 were seen trading with gains. Among these 6 smallcaps namely - Le Travenues Technology (ixigo), Hinduja Global Solutions (HGS), Radhika Jeweltech, Ksolves India, Gujarat Apollo Industries and Mirc Electronics - rallied in the range of 9 - 20 per cent, and in the process gave a breakout on the daily
&w=3840&q=100)
Business Standard
an hour ago
- Business Standard
SBI stock hits highest level in CY-2025 on QIP plan; more upside ahead?
State Bank of India (SBI) share price today Shares of State Bank of India (SBI) were up 1 per cent at ₹840.35 on the BSE in Thursday's intra-day trade after the state-owned lender launched a share sale to institutional investors to raise upto ₹25,000 crore. The stock price of public sector bank was trading higher for the fourth straight day, gaining 4 per cent during the period. SBI shares traded at their highest level in calendar year 2025 (CY25), surpassing the previous current year high of ₹835.40 touched on April 22, 2025. However, thus far in the CY25, SBI has underperformed the market, by gaining 5 per cent, as compared to 5.3 per cent rise in the BSE Sensex. At 09:46 AM; SBI was quoting 0.14 per cent higher at ₹832.70, as against 0.10 per cent decline in the benchmark index. SBI, the largest lender in the country, has launched a share sale to institutional investors to raise upto ₹25,000 crore, the biggest qualified institutional placement (QIP) so far by an Indian firm, and has set a floor price of ₹811.05, which is at a 2.5 per cent discount on Wednesday's closing price. Separately, the bank's board approved another ₹20,000 crore fund raise by issuing bonds. Life Insurance Corporation, Singapore's GIC, Capital International, and ICICI Prudential AMC are some of the investors in the share sale, Business Standard reported quoting investment-banking sources. SBI in Preliminary Placement Document said the Bank intends to utilize the net Proceeds towards augmentation of Bank's TierI capital base to meet Bank's future capital requirements and to support growth plans and to enhance the business of the Bank. Indian Economy The Reserve Bank of India (RBI) has projected the real GDP to grow at 6.5 per cent in 2025-2026, same as in 2024-2025, supported by buoyant rural demand, revival in urban demand, an uptick in investment activity on the back of above-average capacity utilisation, government's continued thrust on capex and congenial financial conditions. The continued momentum in various high frequency indicators of services sector, robust agricultural production and above normal southwest monsoon forecasts, and strong goods and services tax (GST) collections underscore the sustained momentum and resilience of the economy. The soundness and resilience of Scheduled Commercial Banks (SCBs) are bolstered by robust capital buffers, multi-decadal low non-performing loans and strong earnings. The Indian financial sector remained strong and resilient amidst global headwinds. SCBs continued to record improvement in their asset quality, with the gross non-performing asset (GNPA) ratio and net non performing asset (NNPA) ratio declining to multi-decadal lows of 2.3 per cent and 0.5 per cent, respectively, SBI said in Preliminary Placement Document. ALSO READ | Godrej Properties shares up 2% on acquiring land parcel in Raipur; details Axis Securities view on SBI SBI remains well-poised to sustain its growth momentum, supported by its comfortable loan-to-deposit ratio (LDR), which provides it with levers to accelerate credit growth. With a bulk of its loan book either being MCLR-linked or Fixed rate, the impact of yield repricing would be with a lag, instilling confidence in the management to protect NIMs at ~3 per cent. Analysts at Axis Securities believe SBI could continue to deliver a sustainable RoA of 1 per cent over the medium term, supported by healthy growth visibility across segments, strengthening deposit franchise with focus on CASA deposits, ramping up the fee income profile, and controlled Opex and steady provisions. Meanwhile, those at Motilal Oswal Financial Services believe the bank is well-positioned for sustainable credit growth supported by robust underwriting and a potential corporate capex recovery. "SBI has delivered a robust set of performances in recent years, propelled by steady business and revenue growth as well as controlled provisions. NIM has contracted in recent quarters, and the management has guided for broadly stable margins (negative bias depending on the quantum and timing of rate cuts). The bank has levers in place (CD ratio, MCLR re-pricing, asset mix improvement, etc.) to mitigate the impact arising from moderation in lending yields," they said in a recent report. SBI stock is Motilal Oswal's preferred pick within the PSU Bank space. It has a 'Buy' rating on the stock with a share price target of ₹925. Analysts at IIFL Capital, too, prefer SBI among PSBs, betting on its steady market share, superior asset quality, increased digital push, and better loan mix. The brokerage has a 'Buy' rating with a target price of ₹930 per share.
